Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency

Peptides

Volumn 25, Issue 2, 2004, Pages 275-278

  Langer, Ingrid ^a   Gregoire, Françoise ^a   Nachtergael, Ingrid ^a   De Neef, Philippe ^a   Vertongen, Pascale ^a   Robberecht, Patrick ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

RECEPTOR SUBUNIT; SECRETIN; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR VPAC1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR VPAC2; G PROTEIN COUPLED RECEPTOR; HORMONE RECEPTOR; SECRETIN RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; IC 50; LIGAND BINDING; MUTATION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; ANIMAL; BINDING SITE; CHEMISTRY; DRUG POTENTIATION; HUMAN; PROTEIN BINDING; SYNTHESIS;

ANIMALS; BINDING SITES; HUMANS; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; VASOACTIVE INTESTINAL PEPTIDE;

EID: 1942484472     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2003.12.013     Document Type: Article

References (22)

1. 1 receptor states with different affinities for agonists. Cell Signal. 11:1999;691-696.
2. Ciccarelli E., Svoboda M., De Neef P., Di Paolo E., Bollen A., Dubeaux C.et al. Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells. Eur. J. Pharmacol. 288:1995;259-267.
3. Di Paolo E., De Neef P., Moguilevsky N., Petry H., Cnudde J., Bollen A. et al. Properties of a recombinant human secretin receptor: a comparison with the rat and rabbit receptors. Pancreas. 19:1999;51-55.
4. Gales C., Poirot M., Taillefer J., Maigret B., Martinez J., Moroder L.et al. Identification of tyrosine 189 and asparagine 358 of the cholecystokinin 2 receptor in direct interaction with the crucial C-terminal amide of cholecystokinin by molecular modeling, site-directed mutagenesis, and structure/affinity studies. Mol. Pharmacol. 63:2003;973-982.
5. Gelber E., Granoth R., Fridkin M., Dreznik Z., Brenneman D.E., Moody T.W.et al. A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines. Cancer. 92:2001;2172-2180.
6. 1 receptor. Peptides. 18:1997;1555-1560.
7. 2 receptor subclass. Peptides. 18:1997;403-408.
8. 1 receptor agonists. Peptides. 18:1997;1539-1545.
9. 2/PACAP receptors. Eur. J. Pharmacol. 354:1998;105-111.
10. Gozes I., Lilling G., Glazer R., Ticher A., Ashkenazi I.E., Davidson A. et al. Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J. Pharmacol. Exp. Ther. 273:1995;161-167.
11. 1 receptors in human, rat, and guinea pig. J. Pharmacol. Exp. Ther. 301:2002;37-50.
12. 1 receptors. J. Pharmacol. Exp. Ther. 303:2002;445-460.
13. 2-selective ligands. Mol. Pharmacol. 56:1999;1280-1287.
14. 2 receptor chimeras identify domains responsible for the specificity of ligand binding and activation. Eur. J. Biochem. 265:1999;449-456.
15. 2 receptor. Peptides. 21:2000;1543-1549.
16. 1 receptor. Ann. NY Acad. Sci. 921:2000;352-356.
17. Robberecht P., Gourlet P., Vertongen P., Svoboda M. Characterization of the VIP receptor from SUP T1 lymphoblasts. Adv. Neuroimmunol. 6:1996;49-57.
18. 2 agonist enhances glucose-induced insulin release and glucose disposal a potential therapy for type 2 diabetes. Diabetes. 51:2002;1453-1460.
19. Usdin T.B., Bonner T.I., Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology. 135:1994;2662-2680.
20. Vertongen P., Schiffmann S.N., Gourlet P., Robberecht P. Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain. Peptides. 18:1997;1547-1554.
21. Xia M., Sreedharan S.P., Bolin D.R., Gaufo G.O., Goetzl E.J. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J. Pharmacol. Exp. Ther. 281:1997;629-633.
22. 2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide. J. Biol. Chem. 278:2003;10273-10281.